Mesoblast plunges 30 per cent ahead of milestone meeting
Published
The stem cell treatment maker is under pressure as it faces a crucial test to get its flagship drug approved by the US Food and Drug Administration.
Full ArticlePublished
The stem cell treatment maker is under pressure as it faces a crucial test to get its flagship drug approved by the US Food and Drug Administration.
Full Article